In 2017, O’Rourke et al. enrolled 10 patients with recurrent and multifocal MGMT-unmethylated (unmethylated status is known to confer a significantly lower overall survival45), EGFRvIII-expressing GBM.46 The patients in this study were treated with a single IV infusion of EGFRvIII-CAR-T cells. The gene discussed is MGMT; the disease is glioblastoma.